Cassava Sciences Announces Lead Drug Candidate PTI-125 Is Assigned the Chemical Drug Name ‘sumifilam’ by USANGlobeNewsWire • 08/24/20
Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business ReviewGlobeNewsWire • 08/12/20
Cassava Sciences to Give Keynote Presentation on SavaDx at a Scientific ConferenceGlobeNewsWire • 07/09/20
Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer’s Disease Does Not Meet Primary EndpointGlobeNewsWire • 05/15/20
Cassava Sciences Announces New $2.5 Million Research Grant Award from National Institutes of HealthGlobeNewsWire • 04/23/20
Cassava Sciences Announces Initiation of an Open-Label Study to Evaluate PTI-125 in Patients with Alzheimer’s DiseaseGlobeNewsWire • 03/25/20
Cassava Sciences Announces Clinical Update and Business Progress Across Neuroscience PipelineGlobeNewsWire • 03/19/20
Cassava Sciences Announces Phase 2a Study of PTI-125 Published in The Journal of Prevention of Alzheimer’s Disease (JPAD)GlobeNewsWire • 02/11/20
Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer’s DiseaseGlobeNewsWire • 01/28/20
Cassava Sciences: An Investment Opportunity With Some Volatile Periods But A Net UpsideSeeking Alpha • 01/14/20
Cassava Sciences Announces Additional Positive Phase 2a Clinical Data in Alzheimer’s Disease at CTAD 2019GlobeNewsWire • 12/06/19
Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial ResultsGlobeNewsWire • 10/29/19
Cassava Sciences’ Clinical Results in Alzheimer’s Selected as Late-Breaking News at CTAD 2019GlobeNewsWire • 10/24/19